{
    "root": "342983dc-ded9-2234-e063-6294a90ac97f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Repaglinide",
    "value": "20250502",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MEGLUMINE",
            "code": "6HG8UB2MUY"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "POLACRILIN POTASSIUM",
            "code": "0BZ5A00FQU"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "REPAGLINIDE",
            "code": "668Z8C33LU"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.\n                  \n                     Limitation of Use:\n                  \n                  Repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.",
    "contraindications": "The recommended starting dose is 0.5 mg orally before each meal if HbA1c is less than 8%; and 1 or 2 mg orally before each meal if HbA1c is 8% or greater. ( 2.1 ) The recommended dose range is 0.5 mg to 4 mg before meals, with a maximum daily dose of 16 mg. ( 2.1 ) The patient’s dose should be doubled up to 4 mg with each meal until satisfactory glycemic control is achieved. At least one week should elapse to assess response after each dose adjustment. ( 2.1 ) Instruct patients to skip the dose of repaglinide tablets if a meal is skipped. In patients who experience hypoglycemia, the dose of repaglinide tablets should be reduced. ( 2.1 ; 5.1 ) Instruct patients to take repaglinide tablets within 30 minutes before meals. ( 2.1 ) In patients with severe renal impairment (CrCl = 20 – 40 mL/min), recommended starting dose is 0.5 mg orally before each meal. ( 2.2 ) Dose modifications are required when used concominantly with some medications. ( 2.3 , 7 )",
    "warningsAndPrecautions": "Repaglinide Tablets, USP are available as follows:\n                  0.5 mg, white to off-white colored, round tablet debossed with\n \n  ‘CE’on one side and\n \n  ‘251’on the other side.\n\n \n                  NDC 62135-946-90, bottle of 90 tablets\n                  1 mg, yellow to pale yellow, slightly mottled, round tablet debossed with\n \n  ‘CE’on one side and\n \n  ‘252’on the other side.\n\n \n                  NDC 62135-947-90, bottle of 90 tablets\n                  2 mg, yellow to pale yellow, slightly mottled, capsule shaped tablet debossed with\n \n  ‘CE’on one side and\n \n  ‘253’on the other side.\n\n \n                  NDC 62135-948-90, bottle of 90 tablets\n                  Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature].\n                  Protect from moisture. Keep bottles tightly closed.\n                  Dispense in tight containers with safety closures.",
    "adverseReactions": "Repaglinide tablets are contraindicated in patients with:\n                  \n                     Concomitant use of gemfibrozil\n  \n   [see\n   \n    Drug Interactions (7.1)]\n  \n   .\n \n  \n                     Known hypersensitivity to repaglinide or any inactive ingredients."
}